Cheng Peng

University of Science and Technology of China — China

Medicine · Health Sciences

12h-index496citations26works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell Adhesion Molecules Research(7), Platelet Disorders and Treatments(5), Immunotherapy and Immune Responses(3), Multiple Myeloma Research and Treatments(3), Chemokine receptors and signaling(3)

Publications26 total

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial
Blood·2025
Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia
Blood·2025
Aria Gen 2 Pilot Dataset
arXiv (Cornell University)·2025Open Access
Effects of intravaginal conjugated oestrogen on pessary continuation for pelvic organ prolapse: multicentre, randomised, double blind, placebo controlled trial
BMJ·2025· 3 citedOpen Access
Machine Learning to Predict the Occurrence of Distant Organ Involvement in Primary Lymphoma of Bone: A Mixed Cohort Study Based on the SEER Database and Chinese single-center Data
2025Open Access
Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
Blood·2024· 1 citedOpen Access
791 Transition of young adults with cystic fibrosis: a single-center academic transition program
Journal of Cystic Fibrosis·2024
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Haematology·2024· 24 cited
Development and validation of a machine learning-based postoperative prognostic model for plasma cell neoplasia with spinal lesions as initial clinical manifestations: a single-center cohort study
European Spine Journal·2024· 2 cited
Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study
Therapeutic Advances in Medical Oncology·2024· 5 citedOpen Access
MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner
Leukemia Research·2022· 9 cited
Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study
Journal of Thrombosis and Haemostasis·2021· 12 citedOpen Access
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
Journal of Hematology & Oncology·2021· 66 citedOpen Access
Blockade of SDF‐1/CXCR4 reduces adhesion‐mediated chemoresistance of multiple myeloma cells via interacting with interleukin‐6
Journal of Cellular Physiology·2019· 23 cited
Integrin αvβ6 plays a bi-directional regulation role between colon cancer cells and cancer-associated fibroblasts
Bioscience Reports·2018· 50 citedOpen Access
Characteristics of bone marrow cell dysplasia and its effectiveness in diagnosing myelodysplastic syndrome
Hematology·2017· 4 citedOpen Access
370 Dapoxetine Versus Paroxetine for Premature Ejaculation; A Systematic Evaluation and Meta-Analysis
The Journal of Sexual Medicine·2016
Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC)
Tumor Biology·2015· 30 cited
Interleukin-8 promotes cell migration through integrin αvβ6 upregulation in colorectal cancer
Cancer Letters·2014· 62 cited
SDF-1/CXCR4 axis promotes directional migration of colorectal cancer cells through upregulation of integrin αvβ6
Carcinogenesis·2013· 66 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Weibo Niu(6), Heng Mei(6), Ruibin Huang(6), Xuliang Shen(6), Zhongxing Jiang(6), Jiayong Wang(5), Jun Niu(5), Xiaofan Liu(5), Yi Wang(5), Ben Wang(4), Enyu Liu(4), Song Liu(4), Hu Zhou(4), Renchi Yang(4), Huijie Gao(4), Xiaohui Zhang(4), Yan Li(3), Ying Feng(3), Guangxun Gao(3), Linhua Yang(3)